The present invention relates to therapeutic combinations of [3R*(1R*,2S*)]-[3[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydr oxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (141W94), 3'-azido-3'-deoxythymidine (zidovudine) and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol (1592U89) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.

De onderhavige uitvinding heeft op therapeutische combinaties van [ 3R*(1R*, oxy-1-phenylmethyl)propyl]carbamic zuur 2S*)]-[3[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2, tetrahydro-3-furanylester (141W94) betrekking, 3'-azido-3'-deoxythymidine (zidovudine) en (1S, 4R)-GOS-4-[2-AMINO-6(CYCLOPROPYLAMINO)-9H-purin-9-yl]-2-cyclopentene-1 - methanol (1592U89) wat activiteit anti-hiv hebben. De onderhavige uitvinding is ook betrokken met farmaceutische samenstellingen bovengenoemde combinaties bevatten en hun gebruik die in de behandeling van HIV besmettingen met inbegrip van besmettingen met HIV mutanten die weerstand tegen nucleoside en/of niet-nucleosideinhibitors dragen.